Cervetti G - Search Results

1

Characterization of Ph-negative abnormal clones emerging during imatinib therapy.

Abruzzese E, Gozzetti A, Galimberti S, Trawinska MM, Caravita T, Siniscalchi A, Cervetti G, Mauriello A, Coletta AM, De Fabritiis P. Abruzzese E, et al. Among authors: cervetti g. Cancer. 2007 Jun 15;109(12):2466-72. doi: 10.1002/cncr.22699. Cancer. 2007. PMID: 17503437 Free article.

2

Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma.

Riccioni R, Galimberti S, Cervetti G, Fazzi R, Caracciolo F, Petrini M. Riccioni R, et al. Among authors: cervetti g. Leuk Lymphoma. 2002 Sep;43(9):1803-6. doi: 10.1080/1042819021000006448. Leuk Lymphoma. 2002. PMID: 12685835

3

Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib.

Cervetti G, Galimberti S, Fazzi R, Papineschi F, Azzarà A, Simi P, Petrini M. Cervetti G, et al. Eur J Clin Invest. 2004 Mar;34(3):243-4. doi: 10.1111/j.1365-2362.2004.01310.x. Eur J Clin Invest. 2004. PMID: 15025685 No abstract available.

4

Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

Galimberti S, Cervetti G, Cecconi N, Fazzi R, Pacini S, Guerrini F, Manetti C, Caracciolo F, Petrini M. Galimberti S, et al. Among authors: cervetti g. J Immunother. 2004 Sep-Oct;27(5):389-93. doi: 10.1097/00002371-200409000-00007. J Immunother. 2004. PMID: 15314547 Clinical Trial.

5

Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma.

Cervetti G, Galimberti S, Cecconi N, Caracciolo F, Petrini M. Cervetti G, et al. J Chemother. 2004 Aug;16(4):388-91. doi: 10.1179/joc.2004.16.4.388. J Chemother. 2004. PMID: 15332715 Clinical Trial.

6

Rituximab as treatment for minimal residual disease in hairy cell leukaemia.

Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M. Cervetti G, et al. Eur J Haematol. 2004 Dec;73(6):412-7. doi: 10.1111/j.1600-0609.2004.00325.x. Eur J Haematol. 2004. PMID: 15522063 Clinical Trial.

7

Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.

Cervetti G, Galimberti S, Carulli G, Petrini M. Cervetti G, et al. Leuk Res. 2005 Sep;29(9):1097-8. doi: 10.1016/j.leukres.2005.02.014. Leuk Res. 2005. PMID: 16038739 No abstract available.

8

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.

Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M. Galimberti S, et al. Among authors: cervetti g. Cancer Genet Cytogenet. 2005 Oct 1;162(1):57-62. doi: 10.1016/j.cancergencyto.2005.01.015. Cancer Genet Cytogenet. 2005. PMID: 16157201

9

High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases.

Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M. Cervetti G, et al. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):877-80. Clin Exp Rheumatol. 2005. PMID: 16396708 Clinical Trial.

10

Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11).

Buda G, Orciuolo E, Cecconi N, Galimberti S, Cervetti G, Petrini M. Buda G, et al. Among authors: cervetti g. Leuk Res. 2007 Dec;31(12):1765-6. doi: 10.1016/j.leukres.2007.01.009. Epub 2007 Feb 22. Leuk Res. 2007. PMID: 17320954 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters